Want to see GB:AVCT full AI Analyst Report?
AVCT Stock Chart & Stats
65.00 p
-0.10 p(-0.19%)
At close: 4:00 PM EST
65.00 p
-0.10 p(-0.19%)
Day’s Range― - ―
52-Week Range33.00 p - 92.00 p
Previous CloseN/A
Volume371.99K
Average Volume (3M)3.07M
Market Cap
£316.17M
Enterprise Value342.34M
Total Cash (Recent Filing)£16.86M
Total Debt (Recent Filing)£14.92M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
On-time Clinical Execution (AVA6103 Dosing)Consistent, on-time trial execution demonstrates operational capability and disciplined program management. Delivering a planned first-in-human dose and aiming for data by late 2026 materially reduces development timeline uncertainty, strengthens credibility with potential partners, and preserves long-term value creation potential for the therapeutic franchise.
Preclinical Differentiation Vs ADCsSubstantial preclinical advantages in tumor exposure and selectivity provide a mechanistic edge that can translate into improved efficacy and safety versus traditional ADCs. This durable platform differentiation increases the likelihood of clinical differentiation, enhances partner interest for licensing, and supports sustainable competitive positioning in oncology.
Expanded IP & Dual‑payload Platform CapabilityA growing IP estate around sustained‑release and dual‑payload technologies creates structural barriers to entry and enhances licensing and partnership value. Dual‑payload capability is a durable product differentiation that can enable unique clinical profiles and multiple commercialisation pathways, supporting long-term monetisation beyond single-asset outcomes.
Bears Say
Eroding Balance Sheet And Leverage ConcernsShrinking equity and a materially reduced asset base weaken financial flexibility and increase refinancing vulnerability. High leverage relative to the compressed equity base limits the company's ability to self-fund development, raises credit and covenant risk, and can amplify dilution or restructuring needs if clinical or partnering timelines slip.
Sustained Negative Cash Flow; Limited RunwayPersistent operating cash outflows and a runway into early Q1 2027 create a prolonged dependency on external funding or deals. This structural cash constraint raises execution risk for multi‑quarter clinical programs, increases probability of dilutive financing or deal concessions, and constrains strategic optionality over the medium term.
Reliance On Partnering To Progress Pivotal Trials/commercialisationA strategy that defers pivotal trials until partner engagement creates a durable dependency on external counterparties. This limits control over trial timing and commercial terms, slows the path to revenue and approval, and concentrates value realization on the company's ability to secure favourable collaborations rather than solely on clinical outcomes.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 33.00 p and its highest was 92.00 p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £316.17M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 75 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on May 19, 2026. The company reported -0.051 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.051 p.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.051 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.959%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―